A recent study shows that even though 83% of people who commit suicide have had healthcare services in the year before their deaths, only about half of these had a mental health diagnosis.
The Action Alliance for Suicide Prevention has released the details of a research plan aimed at reducing suicides in the US by 20% in five years. The public/private partnership (which works through grants from Substance Abuse and Mental Health Services Administration [SAMHSA] and the Department of Health and Human Services [HHS]) examined the research that shows the most promise in reducing suicides and identified where gaps in current suicide research exist.
Olga Waln, MD
Neurologist, Houston Methodist Neurological Institute, Department of Neurology
Dr. Waln has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
We’re all aware that neuroleptics and other dopamine-receptor blocking agents (DRBAs) can cause a variety of movement disorders, often referred to as extrapyramidal syndromes (EPS).
David Mintz, MD
Fellow, American Academy of Psychoanalysis and Dynamic Psychiatry, Staff psychiatrist, Austen Riggs Center, Stockbridge, MA
Dr. Mintz has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
David Mintz, MD, explains how psychodynamic psychopharmacology considers patients’ individuality in making treatment decisions.
A major obstacle in the prevention of depression is the lack of a predictive biomarker in individuals who later develop the disorder. British researchers have shown that the combination of a physiological biomarker—salivary cortisol—and the presence of depressive symptoms might be used to predict the development of major depression in adolescents.
A team of scientists from the University of Michigan Medical School studied a line of stem cells derived from patients with bipolar disorder to determine what, if any, differences could be found between these and the cells of people without the disorder.
Steve Balt, MD, MS
Board Member, The Carlat Report. In private practice in the San Francisco Bay area.
Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America.
There’s a rich history of research suggesting that glutamate may be involved in the pathogenesis of schizophrenia, with an increasing amount of attention being brought to glutamate during the past decade or so.
Rachel Loewy, PhD
Assistant adjunct professor, University of California, San Francisco
Dr. Loewy has disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Rachel Loewy, PhD, explores evidence-based psychosocial interventions for schizophrenia: CBT, multifamily group therapy, supported employment, and cognitive remediation.